2-Methylmercapto-benzolsulfonsaeure-(1)-chlorid | 60036-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methylmercapto-benzolsulfonsaeure-(1)-chlorid
• 英文别名: 2-Thioamethoxybenzolsulfonylchlorid；2-methylthiobenzenesulphonyl chloride；2-methylthiobenzenesulfonyl chloride；2-(Methylsulfanyl)benzene-1-sulfonyl chloride；2-methylsulfanylbenzenesulfonyl chloride
• CAS: 60036-45-5
• 化学式: C₇H₇ClO₂S₂
• mdl: MFCD09734421
• 分子量: 222.716
• InChiKey: ALICADXOSCQKJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  67.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Methylmercapto-benzolsulfonsaeure-(1)-chlorid 在 氨 作用下， 以 丙酮 为溶剂， 生成 2-Thiomethoxybenzolsulfonamid
  参考文献：
  名称：

  N'-(substituted-1,3,5-

  摘要：

  一种选择性除草剂的化学式为##STR1##，其中m为0、1或2，R.sup.5为有机基团，R.sup.3为氢或有机基团，R.sup.9为氢或可选择取代的烷基基团，R.sup.10为有机基团或与R.sup.9形成环，R.sup.40和R.sup.41为烷基或烷氧基，M为氢或金属或铵基团，或其酸加合物。

  公开号：

  US04743294A1
• 作为产物：
  描述：

  2-氨基茴香硫醚 生成 2-Methylmercapto-benzolsulfonsaeure-(1)-chlorid
  参考文献：
  名称：

  DIEHR, H. -J.;FEST, C.;KIRSTEN, R.;KLUTH, J.;MUELLER, K. -H.;PFISTER, T.;+

  摘要：

  DOI：

文献信息

• Inhibitors of cytosolic phospholipase A2
  申请人：Wyeth

  公开号：US20030144282A1

  公开（公告）日：2003-07-31

  This invention provides substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

  这项发明提供了一般式如下的取代吲哚化合物： 1 及其药用可接受的盐形式，以及将这些化合物用作各种磷脂酶酶的抑制剂的方法，特别是磷脂酶A 2 酶，并用于医疗治疗、预防和抑制疼痛和炎症。
• Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
  申请人：Clerin Valerie

  公开号：US20080009485A1

  公开（公告）日：2008-01-10

  This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

  这项发明提供了一种使用通式所示的取代吲哚化合物及其药用盐形式的方法。该发明提供了一种在哺乳动物中治疗或预防血栓形成，或预防血栓形成症状进展的化合物使用方法。
• Method for making a substituted benzene compound
  申请人：Rohm and Haas Company

  公开号：US05670691A1

  公开（公告）日：1997-09-23

  A method for making a substituted benzene compound includes reacting a 2-substituted benzenesulfonate or the 2-substituted benzenesulfonate further substituted in the 3, 4 or 5-position with a lithium compound to form an intermediate; and reacting the intermediate with an electrophile to form a 2,6-disubstituted benzenesulfonate or a 2,6-disubstituted benzenesulfonate further substituted in the 3, 4 or 5-position.

  制备取代苯化合物的方法包括将2-取代苯磺酸盐或在3、4或5位进一步取代的2-取代苯磺酸盐与锂化合物反应以形成中间体；然后将中间体与亲电试剂反应，形成2,6-二取代苯磺酸盐或在3、4或5位进一步取代的2,6-二取代苯磺酸盐。
• [EN] TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM<br/>[FR] TRIAZINANES POSSÉDANT DES GROUPES À EXTRÉMITÉ THIOSULFONATE ET LEURS PROCÉDÉS DE FABRICATION
  申请人：FLEXSYS AMERICA LP

  公开号：WO2021216487A1

  公开（公告）日：2021-10-28

  The present invention is directed to compounds represented by the formula (I): wherein R1 comprises a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. wherein R2 comprises an alkylene group, an arylene group, or a heterocyclic group. The three R2 groups may be the same or different. wherein A comprises an alkyl, an aryl, or an alkylaryl group. The three A groups may be the same or different.39

  本发明涉及由以下式（I）表示的化合物：其中R1包括一个氢原子或具有1至2个碳原子的烷基基团。其中R2包括一个烷基基团、芳基基团或杂环基团。三个R2基团可以相同也可以不同。其中A包括一个烷基、芳基或烷基芳基基团。三个A基团可以相同也可以不同。
• [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001025200A1

  公开（公告）日：2001-04-12

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物式为（I）（其中R1是氢原子，可被取代的碳氢基团，可被取代的非芳香杂环基团，R2是可被取代的碳氢基团，可被取代的非芳香杂环基团，或R1和R2可以与A一起结合形成可被取代的杂环基团；A是N或N+ -R5 • Y-（R5是碳氢基团；Y-是反离子）；R3是可被取代的环烃基团或可被取代的杂环基团；n为0或1；R4是氢原子，可被取代的碳氢基团，可被取代的杂环基团，可被取代的烷氧基，可被取代的芳氧基，或可被取代的氨基，E是可被除氧基以外的基取代的二价脂肪烃基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团；前提是当G2是OCO时，J是甲基，当另一个是键时，其中一个不是键，当G1是键时，Q和R中的每一个都没有被氧基团取代）或其盐具有强效的CCR5拮抗活性，并可用于人类各种HIV感染疾病（例如艾滋病）的治疗或预防。